VET3-TGI, a TGF-Beta Targeting Clinical Oncolytic Virus Developed from the VET Platform for Systemic Delivery
Time: 2:30 pm
day: Day One
Details:
• KaliVir has developed the VET platform to develop oncolytic virus backbones capable of achieving systemic delivery to solid tumors
• VET3-TGI represents the lead internal product from this platform and is undergoing clinical translational development
• In addition to unique intravenous delivery capabilities, VET3-TGI targets TGF-beta within the tumor microenvironment
• Pre-clinical data with this OV have demonstrated mechanisms resulting in multiple complete responses after systemic delivery in multiple mouse tumor models, even in the face of pre-existing anti-viral immunity
